Vertex Q3 product revenue $2.77B (+12% YoY); raises FY guidance to $10.8-10.9B

VERTEX PHARMACEUTICALS INC / MA

2024-Q3 EPS reported -$5.61 revenue$8,108,100,000

GAAP net income $1.0B; non-GAAP net income $1.1B; cash & securities $11.2B.
FY 2024 product revenue guidance raised to $10.8-10.9B from $10.65-10.85B.
PDUFA dates: vanzacaftor triple Jan 2, 2025; suzetrigine Jan 30, 2025; both Priority Review.
Three programs advanced to Phase 3: suzetrigine in DPN, povetacicept in IgAN, VX-880 in T1D.
CASGEVY revenue from first infused patient; 45 ATCs activated globally.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.